Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST‐segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial
Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y12 inhibitors in ST‐segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial
复制标题
除 P2Y12 抑制剂外，糖蛋白 IIb/IIIa 抑制剂治疗 ST 段抬高型心肌梗死的疗效和安全性：POPular Genetics 试验的亚组分析
DOI：
10.1002/ccd.29861
复制
发表时间：
2021
影响因子：
2.3
通讯作者：
J. T. ten Berg
中科院分区：
文献类型：
--
作者：
A. Tavenier;Daniel M. F. Claassens;R. Hermanides;Gerrit J. A. Vos;T. Bergmeijer;J. Kelder;V. Deneer;A. W. van ’t Hof;J. T. ten Berg
糖蛋白IIb/IIIa抑制剂（GPI）仍被用于ST段抬高型心肌梗死（STEMI）接受初级经皮冠状动脉介入治疗（PCI）的患者，尽管关于其临床益处的讨论仍在进行中。
Glycoprotein IIb/IIIa inhibitors (GPI) are still used in patients with ST‐segment elevation myocardial infarction (STEMI) who undergo primary percutaneous coronary intervention (PCI), although discussion about its clinical benefit is ongoing.